Novo Nordisk only prices in management's latest year guidance and underestimates the full market potential. See why I rate ...

A new case study is the latest to suggest that GLP-1 therapy can tamp down people's unhealthy cravings of drugs like alcohol ...

This article showcases a curated list of standout studies over the last week on topics such as cholesterol, GLP-1 drugs for ...

A network meta-analysis reveals age-dependent variations in efficacy of popular diabetes drugs, with SGLT2 inhibitors showing ...

Less than 5% of hospitalized adults with type 2 diabetes received an SGLT2 inhibitor or GLP-1 before being discharged, ...

A recent review shows who newer medications for type 2 diabetes may help the most, particularly in reducing the risk of ...

GLP-1 medications initially were used to help people with diabetes improve their insulin resistance and hunger cravings.

A study conducted using electronic health record data from a collective of U.S. health care systems found that most adults ...

Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative.

These and other GLP1-RA diabetes/weight-loss meds can also boost outcomes for folks battling chronic kidney disease, new ...

GLP-1) receptor agonists, which are used to treat type 2 diabetes and/or obesity, were linked to vision problems in a small study. Here's what doctors have to say.

When I tell people I direct clinical research studies, I often encounter surprise. “Aren’t you a physician?” they ask. It ...